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Metal-nucleic acid interaction studies have been gaining attention due to their biological and 
chemical importance. Nucleic acids are negatively charged bio-polymers and neutralization 
of their negative charge is essential for the stability and function. In the cells, organic positive 
ions (positively charged amino acids and polyamines) and some of the metal ions (e.g. Na+, 
K+, Mg2+...etc) neutralize the charge of nucleic acids. Whereas, interactions of some metal 
ions (e.g. Cd2+, Hg2+…etc) with nucleic acids destabilize the structure. The stability and 
conformation of nucleic acids alter due to metal interactions. Further, metal interactions with 
nucleic acids can bring changes in conformation of ribose, H-bonding and π-π stacking 
interactions. To understand the metal interactions with nucleic acids, various spectroscopic 
techniques are being used. However, X-ray crystallographic technique is advantageous over 
all other spectroscopic techniques since it gives thorough detail of coordination mode and 
structure. However, crystallization of large molecules like nucleic acids with metals is 
associated with great difficulty. In order to simplify the problem, nucleic acid constituents 
and derivatives have been used as model systems for metal-nucleic acid interactions. Nucleic 
acid constituents and derivatives are multidentate ligands. Moreover, binding mode of metal 
with nucleic acid constituents and derivatives depends on various factors include pH, 
temperature, type of metal…etc. Further, understanding of metal nucleic acid interactions can 
aid to develop new anticancer drugs targeting nucleic acids. For example, cisplatin is a 
platinum based anticancer drug, which coordinates to N(7) of guanine in DNA brings cell 
death. There have been several reports in literature on the complexes of metal nucleic acid 
constituents. However, much more research is warranted for thorough understanding of 
metal-nucleic acid interactions.  
           On the other hand, nucleic acid constituents and derivatives are used extensively in 
anticancer drug development. Some of nucleic acid constituent derivatives, 5-Fluro uracil and 
6-Mercaptopurine, are currently in use for the treatment of colorectal cancer and leukemia, 
respectively. Moreover, cisplatin is a platinum based anticancer drug used in the treatment of 
various types of cancers. However, use of these drugs for long time poses severe side effects 
and drug resistance. Most of the side effects are due to non bio-compatibility of drugs. To 
overcome problems associated with present anticancer drugs, bio-compatible metal based 
anticancer drug development could be an attractive and alternative strategy.  
To address this, in this study, we report synthesis of a number of new metal complexes of 
nucleic acid constituents and their derivatives and characterization by various spectroscopic 
techniques. Also, the interactions of Ni, Cu and Zn ions with various nucleic acid constituents 
and their derivatives have been elucidated by single crystal X-ray crystallography. 
Interestingly, Ni, Cu and Zn ions showed various coordination modes to nucleic acid 
constituents and their derivatives. Further, anticancer studies were carried out for all these 
complexes in various cancer cell lines. Several complexes showed better cytotoxicity than the 
well-known drug cisplatin. My thesis work is divided into five parts based on the nature of 
molecules.    




I. Synthesis, X-ray crystallographic and anticancer studies on metal (Zn/Ni) complexes 
of guanine (G) based nucleic acid constituents 
In order to understand (Zn/Ni) interactions with guanine based nucleic acid constituents and 
their anticancer activity, several (Zn/Ni) complexes of 5′-GMP, 5′-IMP and hypoxanthine 
complexes were prepared. The synthesized complexes are (1) [Zn (5′-GMP)]n.11H2O, (2) [Ni 
(5′-GMP)2 Na2 (μ-OH2)3 (H2O)8].2H2O, (3) [Ni (5′-IMP)2Na2 (H2O)12]n.5H2O and (4) [Ni 
(hx)2 (H2O)4] Cl2 [Here 5′-GMP = 5′-Guanosine Mono Phosphate, 5′-IMP = 5′-Inosine Mono 
Phosphate and hx = Hypoxanthine). These complexes were characterized by various 
spectroscopic and X-ray crystallography techniques. Complex 1: The X-ray structure 
revealed that zinc is coordinated to 5′-GMP through N(7) position of purine and phosphate 
moieties, the uncoordinated water molecules are making interesting complicated network of 
hydrogen bonds in the unit cell. The geometry of zinc coordination centre is distorted 
tetrahedral. Fascinatingly, zinc exhibited two different coordination environments. In one 
case, all phosphate oxygens participated in coordination with zinc. In second case, N(7) 
position of purine and phosphate oxygens participated in coordination with zinc. Moreover, 
zinc formed a coordination polymer with 5′-GMP. The conformation of ribose changed upon 
zinc interaction with 5′-GMP from C(3′)-endo to C(2′)-endo, these results suggest that zinc 
interaction with nucleic acids may change their conformation. Complex 1 is stabilized in 
solid state by H-bonding and π-π stacking interactions. Complex 2: In complex 2, 5′-GMP is 
coordinated to nickel through N(7) position of purine but phosphate moiety did not take place 
in coordination. Two molecules of 5′-GMP and four water molecules coordinated to nickel 
and formed distorted octahedral geometry. The charge of complex 2 is balanced by sodium 
coordination to sugar hydroxyl groups and nickel coordinated water molecules. The geometry 
of sodium coordination centre is distorted octahedral. The conformation of 5′-GMP is altered 
due to nickel interaction. Moreover, complex 2 is stabilized in solid state by H-bonding and 
π-π stacking interactions. Complex 3: Nucleotide 5′-IMP also showed similar coordination 
modes like 5′-GMP towards nickel, where N(7) position of purine participated in 
coordination with nickel and phosphate moieties did not coordinate to nickel. Two molecules 
of 5′-IMP and four water molecules participated in coordination with nickel and formed 
distorted octahedral geometry. Interestingly, the charge of complex 3 is balanced by sodium 
coordination to sugar hydroxyl moieties. The geometry of sodium coordination centre is 
distorted octahedral. Moreover, nickel is forming coordination polymer with 5′-IMP. Further, 
nickel interactions with 5′-IMP brought changes in the conformation of ribose moiety. These 
results suggest that nickel interactions with nucleic acids may bring changes in their 
conformation. Interestingly, right hand helical structure formation is observed for complex 3 
in crystal structure. Further, the chirality of complex 3 was confirmed by circular dichroism 
studies. Complex 3 is stabilized by both H-bonding and π-π stacking interactions in solid 
state. Complex 4: Surprisingly, nickel is coordinated to hypoxanthine through N(9) position 
of purine in acidic conditions and not through N(7) or N(3). The coordination mode of nickel 
with hypoxanthine is different from complexes 2 and 3. Two hypoxanthine moieties are 
coordinated to nickel in axial manner. The geometry of nickel coordination centre is distorted 




octahedral. Further, complex 4 is stabilized by H-bonding and π-π stacking interactions in 
solid state. Cytotoxicity studies of complexes 1-4 on various cancer cell lines revealed that 
complex 1 is better cytotoxic than complexes 2-4. Moreover, complex 1 exhibited 
comparable cytotoxicity with cisplatin on various cells lines and induced apoptotic cell death. 
II. Synthesis, structure elucidation and anticancer activity of copper-adeninyl 
complexes 
In order to understand copper-adenine interactions and anticancer activity, several copper 
complexes of adenine derivatives were prepared. Here, most of adenine derivatives used in 
complex preparation is known as cycline dependent kinase inhibitors. Prepared copper 
complexes are 1) [Cu (N6-benzyl adenineH)2Cl3 ].Cl.2H2O, 2) [Cu (2-amino-N
6-
benzyladenineH)2Cl3].(2-amino-N
6-benzyl adenineH)2.3Cl.5H2O, 3) [Cu (α-(Purin-6-
ylamino)-p-toluenesulfonamide H)2Cl4], 4) [Cu (kinetinH)2 Cl3].Cl.2H2O, 5) [Cu (N-1H-
purine-6-yl-alanineH) (H2O) Cl3].H2O, 6) [(Cu (N-1H-purine-6-yl-alanineH)2Cl3).(Cu(N-1H-
purine-6-yl-alanineH)Cl)2(μ-Cl)2].Cl.4H2O. All these complexes were characterized by X-ray 
crystallography and various spectroscopic techniques. Complex 1: Synthesis and X-ray 
structures of complex 1 were reported in literature. However, anticancer activity of complex 
1 is not known. Therefore, it was prepared based on the reported lines to assess the anticancer 
activity. The anticancer activity of complex 1 was studied on various cell lines. Interestingly, 
complex 1 exhibited better cytotoxicity than cisplatin in MCF-7 and MDA-MB-231 cell 
lines. Complex 2: Ligand 2-amino-N6-benzyl adenine is coordinated to copper through N(9) 
of purine. In addition, two uncoordinated 2-amino-N6-benzyl adenine, three chloride and five 
water molecules are making it as a co-complex with uncoordinated ligands. The copper 
coordination centre adopted distorted trigonal bipyramidal geometry [3+2] with τ = 0.671 (α-
β/60, where α, β are two greatest valence angles of coordination centre). Further, complex 2 
is stabilized in solid state by both H-bonding and π-π stacking interactions. H-bonding is 
observed between N-H···Cl. Uncoordinated water molecules formed six-member rings with 
H-bonding network. The π-π stacking interactions are observed between phenyl and purine 
moieties. Complex 2 exhibited better cytotoxicity than 2-amino-N6-benzyl adenine and 
copper salt. Complex 3: Ligand α-(2-Amino purin-6-ylamino)-p-toluene sulfonamide is 
coordinated to copper through N(9) position and protonation is observed at N(3) position. 
Two molecules of α-(2-Amino purin-6-ylamino)-p-toluene sulfonamide and four chloride 
ions are forming a distorted octahedral geometry with copper. Complex 3 is stabilized by N-
H···Cl and N-H···O H-bonding. Further, complex 3 exhibited better cytotoxicity than 
cisplatin in U251 cells. Complex 4: Kinetin is coordinated to copper through N(9) position of 
purine. Protonation is observed on N(3) position and balanced the charge of complex 4. Two 
molecules of kinetin and three chloride moieties are coordinated to copper and forming 
distorted trigonal bipyramidal geometry [3+2] with τ = 0.431. Moreover, complex 4 is 
stabilized by both H-bonding interactions and π-π stacking interactions. The H-bonding of 
complex 4 is observed between N-H···Cl and C-H···Cl. The π-π stacking interactions are 
observed between furanyl aromatic ring and imidazole ring of purine. Complex 4 exhibited 




better cytotoxicity than kinetin and copper salt. Complex 5: The N-1H-purine-6-yl-alanine is 
coordinated to copper through N(9) position of purine. Complex 5 crystallizes in the 
monoclinic space group P21 with Z=4. One molecule of N-1H-purine-6-yl-alanine, two 
chloride ions and one water molecule coordinated to copper. The geometry of copper 
coordination centre is distorted trigonal bipyramidal [3+2] with Cu(1) τ1 = 0.613 and Cu(2) 
τ2= 0.671. Protonation is observed on N(3) position. Complex 5 is stabilized by both H-
bonding and π-π stacking interactions. The H-bonding of complex 5 is observed between N-
H···Cl and C-H···Cl. The π-π stacking interactions are observed between imidazole moieties. 
Moreover, complex 5 exhibited better cytotoxicity than N-1H-purine-6-yl-alanine and copper 
salt. Complex 6: Complex 6 is a co-complex, where two different complexes are co-
crystallized. The crystal structure of complex 6 indicate that geometry of Cu(1) and Cu(2) 
coordination centre are distorted trigonal bipyramidal [3+2] with τ1 = 0.3261 and τ2 = 0.8, 
respectively. Two molecules of N-1H-purine-6-yl-alanineH are coordinated to Cu(2) through 
N(9) position of purine. The N-1H-purine-6-yl-alanineH ligands are arranged in geometry in 
trans manner with respect to axis passing through the N(9) atom and copper. Whereas, in 
second co-complex two N-1H-purine-6-yl-alanineH are coordinated to Cu(1) through N(9) 
and N(3) position of purine. Both Cl(1) and Cl(3) coordinated to copper are forming a bridge 
between copper. In addition, one uncoordinated chloride and two water molecules are present 
in the unit cell. Complex 6 is stabilized in crystalline state by both H-bonding and π-π 
stacking interactions. Complex 6 exhibited better cytotoxicity than complex 5, N-1H-purine-
6-yl-alanine and copper salt on various cell lines. 
III. Synthesis, structure and anticancer activity of zinc complexes of adenine derivatives 
In order to understand zinc interaction with adenine and their anticancer activity, several zinc 
complexes of adenine derivatives were prepared. The prepared complexes  are (1) [Zn (N6-
benzyladenineH).Cl3].2H2O, (2) [Zn2 (μ -N6-benzyladenine)2( μ-H2O)2(H2O)4].(OTf)4.H2O, 
(3) (N6-benzyl adenineH2) [ZnCl4].2H2O, (4) [Zn (2-Amino-N
6-Benzylpurine)Cl3).2-Amino-
N6-BenzylpurineH).EtOH, (5) (2-Amino-N6-(3-picoyl)purineH2)[ZnCl4].H2O, (6)(2-Amino-
N6-(3-picoyl)purineH2)[ZnCl4].HCl, (7) (2-Chloro-N
6-(3-picoyl) purineH2) [ZnCl4].H2O, (8) 
((α-Purine-6-ylamino)-p-toluene sulfonamide H)2[ZnCl4].2HCl.2H2O. Complex 1: The N6-
benzyl adenine is coordinated to zinc through nitrogen atom N(7) of purine. One molecule of 
N6-benzyl adenine and three chloride ions are coordinated to zinc and forming distorted 
tetrahedral geometry. Interestingly, the nitrogen atom N(1) of purine is protonated. Complex 
1 exhibited strong H-bonding interactions between N-H···O, N-H···Cl and N-H···N. The 
complex 1 showed better cytotoxicity than N6-benzyl adenine and ZnCl2. Complex 2: The 
N6-benzyl adenine formed a dimeric complex with zinc at neutral pH. Complex 2 crystallizes 
in the triclinic space group P-1with Z=1. Two Zn metal centres are bridged by two molecules 
of N6-benzyl adenine through nitrogen atoms N(3) and N(9) of purine forming a di-nuclear 
complex, further two zinc centres is bridged by two water molecules and other two water 
molecules on the other side completing the octahedral coordination for the Zn. Complex 2 is 
stabilized in crystalline state by H-bonding interactions. The H-bonding of complex 2 is 




observed between O-H···O and N-H···O. Complex 2 exhibited better cytotoxicity than N6-
benzyl adenine and ZnCl2 on various cell lines. Complex 3: The N
6-benzyladenine is not 
coordinated to the Zn metal at acidic pH and forms an ion-pair complex. Ion-pair complex 3 
crystallizes in the monoclinic space group Cc with Z=4. The protonation is observed at N(1) 
and N(9) atoms of N6-benzyl adenine. The positive charges on N6-benzyl adenine is 
neutralized by the presence of two chloride ions in [ZnCl4]
2-. Alternative arrangement of 
cation and anion arrangement is observed in complex 3. Water channel formation is observed 
between cation and anion arrangement. Moreover, complex 3 is stabilized by H-bonding and 
π-π stacking interactions. H-bonding is observed in complex 3 between N-H···Cl, O-H···Cl 
and N-H···O. The π-π stacking interactions in complex 3 are observed between benzyl six-
membered aromatic ring and purine six-membered rings. Complex 3 exhibited better 
cytotoxicity than N6-benzyl adenine and ZnCl2 in various cell lines. Complex 4: Ligand 2-
amino-N6-benzyl adenine resulted in a different structure from N6-benzyl adenine with zinc. 
One molecule of 2-amino-N6-benzyl purine is coordinated to zinc through nitrogen atom N(7) 
of purine. Surprisingly, one uncoordinated positively charged 2-amino-N6-benzyl purineH is 
present in the asymmetric unit, which is balancing the charge of zinc complex 4. Protonation 
is observed on N(3A) atom. Interestingly, tautomeric proton is located on coordinated purine 
of N(9) atom and uncoordinated purine of N(7A) atom. Geometry of ‘Zn coordination centre’ 
is distorted tetrahedral. Complex 4 is stabilized by H-bonding and π-π stacking interactions. 
The H-bonding interaction in complex 4 is observed between N-H···O and N-H···Cl. The π-π 
stacking interactions are observed between five-member aromatic rings and six-membered 
aromatic rings. Complex 4 exhibited better cytotoxicity than 2-amino-N6-benzyl purine and 
ZnCl2 in various cell lines. Complex 5: 2-Amino-N
6-(3-picoyl) purine forms an ion-paired 
complex with zinc at acidic pH. The protonation in 2-Amino-N6-(3-picoyl) purine is observed 
at N(3) of the purine and picolyl N(14). The positive charge of 2-Amino-N6-(3-picoyl) purine 
is neutralized by the presence of two chloride ions in [ZnCl4]
2-. Moreover, complex 5 
exhibited both H-bonding interactions and π-π stacking interactions. The H-bonding 
interactions are observed between N-H···Cl, N-H···N, O-H···Cl, N-H···O and C-H···N. One 
uncoordinated water molecule is present in unit cell, which is involved in H-bonding with 
both ions. The π-π stacking interactions are observed between purine five-membered rings 
and purine six-membered ring. Complex 5 exhibited better cytotoxicity than cisplatin in 
HeLa and MDA-MD-231 cells. Complex 6: 2-Amino-N6-(3-picoyl) purine formed similar 
structure of complex 5 in strong acidic conditions. Complex 6 exhibited both H-bonding and 
π-π stacking interactions. The H-bonding in complex 6 is observed between N-H···Cl and N-
H···N. In complex 6, the π-π stacking interactions are observed between pyridyl six-
membered rings and purine six-membered rings. Purine-Purine stacking interactions are 
observed between purine six-membered ring and five-membered rings. Complex 6 exhibited 
better cytotoxicity than cisplatin in HeLa, MCF-7, MDA-MB-231 and HeLa-Dox cells. 
Interestingly, complex 6 arrested (G2/M phase) cell cycle in HeLa and MCF-7 at higher 
concentration and induced apoptosis. Complex 7: 2-chloro-N6-(3-picoyl) purine formed ion-
pair complex with zinc. The protonation in 2-chloro-N6-(3-picoyl) purine is observed on N(9) 




of purine and N(14) of picolyl atoms. The positive charge of 2-chloro-N6-(3-picoyl) purine is 
neutralized by the presence of two chloride ions in [ZnCl4]
2-. Complex 7 is stabilized by both 
H-bonding and π-π stacking interactions. The H-bonding is observed between N-H···Cl, O-
H···Cl and N-H···O in complex 7. The π-π stacking interactions are observed between 
pyridyl six-membered ring and six-membered ring of purine. Complex 7 exhibited better 
cytotoxicity than cisplatin in HeLa, MCF-7, U251 and HeLa-Dox cells. Complex 8: (α-
Purine-6-ylamino)-p-toluene sulphonamide formed ion-pair complex with zinc. Ion-pair 
complex 8, crystallizes in the triclinic space group P-1 with Z=4. The protonation on (α-
Purine-6-ylamino)-p-toluene sulfonamide is observed at N(9) and N(1) atoms of purine. The 
positive charge of the ligand is neutralized by two chloride ions present in [ZnCl4]
2-. The H-
bonding is observed between N-H···Cl, O-H···N, N-H···O and O-H···Cl. The π-π stacking 
interactions are observed between benzyl rings of benzene sulfonamide moieties. Complex 8 
exhibited better cytotoxicity than cisplatin in HeLa, MCF-7 and HeLa-Dox cells. Moreover, 
these complexes induced apoptotic cell death as revealed by Annexin V/PI assay, FACS and 
microscopy analysis.  
IV. Synthesis, structure and cytotoxicity studies of zinc complexes of uracil-1-acetic acid 
and N6-adeninebutyric acid 
To understand the zinc interactions with nucleic acid constituent derivatives and their 
anticancer activity, zinc complexes of uracil-1-acetic acid and N6-adeninebutyric acids were 
prepared. (1) [Zn (uracil-1-acetato)2 (H2O)4] and complex (2) [Zn (N
6-adeninebutyric acid)2 
(H2O)2]) were characterized by X-ray crystallography and various spectroscopic techniques. 
The X-ray structures showed acetate moiety coordination to zinc rather than purine and 
pyrinidine moities. The geometry of zinc coordination centre is distorted octahedral. 
Complexes 1 and 2 are stabilized by non-covalent interactions. Anticancer studies of these 
complexes showed better cytotoxicity than cisplatin in MDA-MB-231cells.   
V. Copper (II) complexes of 6-mercaptopurine, hypoxanthine and uracil-1-acetic acid: 
Synthesis, structures, antioxidant and potent anticancer activity 
To delineate copper interactions with purine and pyrimidine derivatives and anticancer 
activity, several copper complexes of 6-mercaptopurine, hypoxanthine and uracil-1-acetic 
acid were prepared. The prepared complexes are (1) [Cu (6-MP) (bpy) Cl2], (2) [Cu (hx) 
(phen) Cl2].H2O and (3) [Cu (bpy)2 (uracil-1-acetato)].6H2O)] (bpy = 2, 2′-bipyridine, phen = 
1, 10-phenanthroline, 6-MP = 6-Mercapto Purine and hx = hypoxanthine). All these 
complexes were chracterized by various spectroscopic and X-ray diffraction techniques. 
Complexes 1 and 2 crystallize in the monoclinic space groups Cc and C2/c, respectively with 
eight molecules in the unit cell. All the complexes 1-3 adopt distorted trigonal bipyramidal 
geometry. Surprisingly, most potent coordination sites of sulfur in 6-MP and acetato in 
uracil-1-acetato did not participate in coordination with copper. In complexes 1 and 2, the 
N(7) position of purine and the N(3) position of pyrimidine in complex 3 are coordinated 
with copper. All these complexes 1-3 are stabilized by non-covalent interactions in solid 




state. Anticancer studies showed better cytotoxicity for copper complexes than cisplatin, 6-
meracptopurine and temozolomide in various cell lines. Interestingly, copper complexes of 6-
MP and hypoxanthine showed antioxidant activity and reduced ROS level in cells. In 
contrast, copper complex of uracil-1-acetic acid produced ROS in cells. In contrast, copper 
hypoxanthine showed better cytotoxicity than cisplatin in HeLa-Dox cells. All these 
complexes induced apoptotic cell death.  
                  In summary, we studied the interaction of metal-nucleic acid constituents and 
derivatives by X-ray crystallography. We found new coordination modes for Ni, Cu and Zn 
towards various nucleic acid constituents and derivatives. Some of these complexes showed 
better cytotoxicity than well known anticncer drugs cisplatin, 6-meracptopurine and 
temozolomide. Complex [Cu (hx) (phen) Cl2].H2O showed better cytotoxicity than cisplatin 
in doxorubicin resistant (HeLa-Dox) cells. These complexes induced apoptotic cell death in 
various cancer cells. All in all, the results of present studies/findings could form a potential 
lead for the development of newer anticancer therapeutics. 
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